← All trials
NCT05116683
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2021
- Primary completion
- Feb 28, 2023
- Completion date
- Feb 28, 2026
- First posted
- Nov 11, 2021
- Last posted
- Nov 11, 2021
- Enrollment
- 34
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Columbia UniversityLead sponsor
- Columbia UniversityReponsible party - principal investigator
- Columbia UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.